Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Breast Cancer Susceptibility Protein 2 Antibody is a Rabbit Polyclonal against Breast Cancer Susceptibility Protein 2.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Breast Cancer Susceptibility Protein 2 (BRCA2) |
| Host | Rabbit |
| Reactivity | Mouse |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Purification | Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P97929 |
| Alias | BRCC2,BROVCA2,FACD, FAD,FAD1,FANCD,FANCD1,GLM3,PNCA2,XRCC11,Fanconi anemia group D1 protein |
| Background | Antibody anti-BRCA2 |
| Status | RUO |
| Note | Concentration: 1 mg/ml - |
Descripción
BRCA2 is a tumor suppressor protein that plays a pivotal role in maintaining genomic stability by facilitating the repair of DNA double-strand breaks through homologous recombination. It interacts with RAD51, a recombinase protein, to mediate the precise alignment and strand exchange during DNA repair. Structurally, BRCA2 contains eight BRC repeats that directly bind RAD51 and a DNA-binding domain that targets damaged DNA regions. Mutations in the BRCA2 gene are strongly associated with an increased risk of hereditary breast, ovarian, and other cancers, such as pancreatic and prostate cancer. These mutations often lead to truncated or dysfunctional proteins, resulting in impaired DNA repair and genomic instability, which drives tumorigenesis. Beyond its role in DNA repair, BRCA2 is also implicated in cell cycle regulation and replication fork protection. BRCA2 deficiency is therapeutically targeted using PARP inhibitors, exploiting synthetic lethality to selectively kill BRCA2-mutant cancer cells while sparing normal cells. This approach has revolutionized treatment options for BRCA2-associated cancers, emphasizing its clinical significance.
Related Products
anti- BRCA2 antibody
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA(ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A(RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex(transcription and export complex 2) subunits PCID2 and SHFM1/DSS1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination(PubMed:24896180).
Ver Producto
Recombinant Human BRCA2
Ver Producto
BRCA2 (Phospho-Ser3291) Antibody
Rabbit polyclonal antibody against BRCA2 protein. Immunogen region is C-terminal. Specificity is as follows for the reactive species: H:S3291, M:S3214, R:S3222.
Ver Producto